- Home
- FMS vs MRNA Comparison
FMS vs MRNA Comparison
Compare FMS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMS | MRNA |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | Germany | United States |
| Employees | N/A | 5800 |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 11.5B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FMS | MRNA |
|---|---|---|
| Price | $23.56 | $29.47 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 14 |
| Target Price | $30.00 | ★ $33.25 |
| AVG Volume (30 Days) | 450.8K | ★ 9.8M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | ★ 8.62 | N/A |
| EPS | ★ 2.86 | N/A |
| Revenue | ★ $23,046,819,198.00 | $2,232,000,000.00 |
| Revenue This Year | $2.12 | N/A |
| Revenue Next Year | $2.92 | $0.77 |
| P/E Ratio | $15.93 | ★ N/A |
| Revenue Growth | ★ 2.10 | N/A |
| 52 Week Low | $22.05 | $22.28 |
| 52 Week High | $30.46 | $48.92 |
Technical Indicators
Market Signals| Indicator | FMS | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 65.99 |
| Support Level | $22.63 | $26.90 |
| Resistance Level | $24.20 | $26.00 |
| Average True Range (ATR) | 0.27 | 1.14 |
| MACD | 0.10 | 0.59 |
| Stochastic Oscillator | 59.23 | 85.99 |
Price Performance
Historical ComparisonAbout FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.